

David A Hecht

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7635776/publications.pdf>

Version: 2024-02-01

37
papers

729
citations

706676

14
h-index

651938

25
g-index

38
all docs

38
docs citations

38
times ranked

1138
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure-based design of guanosine analogue inhibitors targeting GTP cyclohydrolase IB towards a new class of antibiotics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 126818.	1.0	0
2	The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance. <i>Journal of Molecular Medicine</i> , 2020, 98, 1161-1173.	1.7	6
3	Discovery of cyclic guanidine-linked sulfonamides as inhibitors of LMTK3 kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127108.	1.0	5
4	Syntheses and Binding Testing of N1-Alkylamino-Substituted 2-Aminobenzimidazole Analogues Targeting the Hepatitis C Virus Internal Ribosome Entry Site. <i>Australian Journal of Chemistry</i> , 2020, 73, 212.	0.5	0
5	Activity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells. <i>Viruses</i> , 2019, 11, 365.	1.5	10
6	Modeling the structural origins of drug resistance to isoniazid via key mutations in <i>Mycobacterium tuberculosis</i> catalase-peroxidase, KatG. <i>Tuberculosis</i> , 2018, 108, 155-162.	0.8	26
7	CUREs in biochemistry—where we are and where we should go. <i>Biochemistry and Molecular Biology Education</i> , 2017, 45, 7-12.	0.5	52
8	Structure-based analysis of Bacilli and plasmid dihydrofolate reductase evolution. <i>Journal of Molecular Graphics and Modelling</i> , 2017, 71, 135-153.	1.3	3
9	The Preorganization of Atropisomers to Increase Target Selectivity. <i>Synlett</i> , 2016, 27, 977-983.	1.0	11
10	Enhancing the selectivity of kinase inhibitors in oncology: a chemical biology perspective. <i>Future Medicinal Chemistry</i> , 2016, 8, 241-244.	1.1	4
11	Exploiting Atropisomerism to Increase the Target Selectivity of Kinase Inhibitors. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 11754-11759.	7.2	51
12	Modeling the evolution of drug resistance in <i>Plasmodium falciparum</i> DHFR. , 2013, , .		0
13	Semantic Computing and Drug Discovery - A Preliminary Report. , 2013, , .		4
14	Modeling the evolution of drug resistance in malaria. <i>Journal of Computer-Aided Molecular Design</i> , 2012, 26, 1343-1353.	1.3	9
15	BioFactory: Semantic Integration of Biomedical Data and Applications. , 2012, , .		0
16	Cefoxitin is both an inhibitor of class A beta-lactamase of <i>Xanthomonas campestris</i> pv. <i>campestris</i> str. 17 and an inducer of its gene. <i>Research in Microbiology</i> , 2012, 163, 550-556.	1.0	6
17	Towards predictive structure-based models of evolved drug resistance. , 2012, , .		2
18	Molecular Modeling Studies of AmpR Mediated AmpC ß-Lactamase Repression. , 2011, , .		1

#	ARTICLE	IF	CITATIONS
19	Applications of machine learning and computational intelligence to drug discovery and development. Drug Development Research, 2011, 72, 53-65.	1.4	19
20	Structural-based analysis of dihydrofolate reductase evolution. Molecular Phylogenetics and Evolution, 2011, 61, 212-230.	1.2	14
21	Machine learning approaches for customized docking scores: Modeling of inhibition of Mycobacterium tuberculosis enoyl acyl carrier protein reductase. , 2010, , .		4
22	Computational Intelligence Methods for Docking Scores. Current Computer-Aided Drug Design, 2009, 5, 56-68.	0.8	33
23	Docking scores and QSAR using evolved neural networks for the Pan-inhibition of wild-type and mutant PfDHFR by cycloguanil derivatives. , 2009, , .		5
24	Describing Dynamic Biological Systems in SPDL and SCDL. , 2009, , .		0
25	SCDL Applications to Drug Discovery. , 2009, , .		1
26	A Novel <i>In Silico</i> Approach to Drug Discovery via Computational Intelligence. Journal of Chemical Information and Modeling, 2009, 49, 1105-1121.	2.5	32
27	Modeling the inhibition of quadruple mutant Plasmodium falciparum dihydrofolate reductase by pyrimethamine derivatives. Journal of Computer-Aided Molecular Design, 2008, 22, 29-38.	1.3	20
28	In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase. Journal of Molecular Graphics and Modelling, 2008, 26, 1145-1152.	1.3	20
29	On the relationship between GC content and the number of predicted microRNA binding sites by MicroInspector. Computational Biology and Chemistry, 2008, 32, 222-226.	1.1	9
30	QSAR using evolved neural networks for the inhibition of mutant PfDHFR by pyrimethamine derivatives. BioSystems, 2008, 92, 10-15.	0.9	31
31	Quantitative structure-property relationships for drug solubility prediction using evolved neural networks. , 2008, , .		7
32	USING SCDL FOR INTEGRATING TOOLS AND DATA FOR COMPLEX BIOMEDICAL APPLICATIONS. International Journal of Semantic Computing, 2008, 02, 291-308.	0.4	10
33	BioSemantic System: Applications of Structured Natural Language to Biological and Biochemical Research. , 2008, , .		1
34	High-Throughput Ligand Screening via Preclustering and Evolved Neural Networks. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2007, 4, 476-484.	1.9	20
35	Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology, 2007, 46, 324-329.	3.6	177
36	Correlating hydration shell structure with amino acid hydrophobicity. Journal of the American Chemical Society, 1993, 115, 3336-3337.	6.6	77

#	ARTICLE	IF	CITATIONS
37	Defining hydrophobicity: probing the structure of solute-induced hydration shells by Fourier transform infrared spectroscopy. <i>Journal of the American Chemical Society</i> , 1992, 114, 4336-4339.	6.6	25